India Plans CV19 Vaccination Roll-out Program
- by Joy Garcia
- in Medicine
- — Jan 3, 2021
It was the first to approve a shot developed by Pfizer of the United States and Germany's BioNTech, with the result that hundreds of thousands of people were vaccinated in Britain before European Union countries and the U.S. even began administering it this month.
"India is possibly the only country where four vaccine candidates are ready", Mr Javdekar said at the ruling Bharatiya Janata Party's briefing on Saturday in New Delhi. Now, Drug Controller General of India (DCGI) will take a final call on rolling out the inoculation.
Covishield has become the first coronavirus vaccine to receive a regulatory nod in India.
These same India government officials report a committee of India's Central Drugs Standard Control Organization is expected to meet to consider these emergency-use applications following studying the safety, efficacy, and immunogenicity data from both the homegrown Bharat and Serum manufacturers as well as the British Oxford-based AstraZeneca. The company has been contracted by AstraZeneca to make 1 billion doses for developing nations, including India.
It added that the objective of the drive is to gear up for the roll out of COVID19 vaccine across the country. That's a daunting task, given the country's vast territory, limited infrastructure and patchy health networks.
The chances of SII looked bright after the Oxford vaccine was approved by the United Kingdom administration.
Robots with rhythm: Boston Dynamics' dancing androids a hit
Today's iteration of the quadruped robot is far more graceful and its motions are smoother than they were two years ago. The robots in the video that was uploaded in video streaming site YouTube were Atlas , the dog robot Spot , and Handle .
The vaccine, developed by CNBG's unit Beijing Biological Products Institute, along with another candidate from a Wuhan-based unit of CNBG, are being tested in Phase III clinical trials outside China.
Aside from the expert committee's deliberations, health activists have raised concerns about the efficacy data of the vaccine. The trials produced two different results from two dosing regimens.
Astrazeneca's vaccine can also be stored at lower temperatures compared to the Pfizer doses, which need to be stored at the ultra-cold temperature of -70 degrees Celsius at all times.
While trial results published in The Lancet found the vaccine to be safe and effective, more analysis will be needed to see how well it works in people over 55, who are among those at higher risk from the pandemic.
"For the Government of India, Covishield (Oxford vaccine) will cost about US$3 per dose, so US$6 [INR 440] per person, but for the private market, it will cost around INR 700-800".
